
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
OPHLY | OTC Markets | USD | Delayed | |
4528 | Tokyo | JPY | Delayed |
Ono Pharmaceutical Co., Ltd. engages in production, purchase, and sale of pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. It also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, for the treatment of Secondary Hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Toichi Takino | 56 | 2020 | President, COO & Representative Director |
Masao Nomura | 75 | 2018 | Independent Outside Director |
Akiko Tanabe | 54 | 2020 | Outside Audit & Supervisory Board Member |
Yasuo Hishiyama | 51 | 2016 | Outside Audit & Supervisory Board Member |
Kiyoaki Idemitsu | 60 | 2021 | Audit & Supervisory Board Member |
Shusaku Nagae | 74 | 2021 | Independent Outside Director |
Akiko Okuno | 54 | 2020 | Independent Outside Director |
Masao Nomura | 75 | 2018 | Independent Outside Director |
Hironobu Tanisaka | 64 | 2021 | Chairman of Audit Supervisory Board |
Toshihiro Tsujinaka | 61 | 2016 | EVP, Executive Director of Corporate Strategy & Planning, HR Division and Representative Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review